This monthly feature will help readers keep current on new drugs, new indications, dosage forms, and safety-related changes in labeling or use. Efforts have been made to ensure the accuracy of this information; however, if there are any questions, please let me know at bakerdan@wsu.edu.
If ribavirin is permanently discontinued for management of anemia, then peginterferon alfa and Victrelis must also be discontinued In clinical trials, the median time to onset of hemoglobin less than 10 g per dL from the initiation of therapy was similar among subjects. Neutropenia (Use with Ribavirin and Peginterferon Alfa)
If peginterferon alfa and ribavirin are permanently discontinued, then Victrelis must also be discontinued.
Laboratory Tests
Complete blood count (with white blood cell differential counts) must be conducted in all patients prior to initiating Victrelis/peginterferon alfa/ribavirin combination therapy. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm303600.htm Clonidine hydrochloride Kapvay (Shionogi)
WARNINGS AND PRECAUTIONS Cardiac Conduction Abnormalities
The sympatholytic action of clonidine may worsen sinus node dysfunction and atrioventricular (AV) block, especially in patients taking other sympatholytic drugs.
There have been postmarketing reports of patients with conduction abnormalities and/or taking other sympatholytic drugs who developed severe bradycardia requiring IV atropine, IV isoproterenol, and temporary cardiac pacing while taking clonidine. Up titrate Kapvay slowly and monitor vital signs frequently in patients with cardiac conduction abnormalities or patients concomitantly treated with other sympatholytic drugs. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm342967.htm 
WARNINGS AND PRECAUTIONS Severe Skin and Hypersensitivity Reactions
Severe, potentially life-threatening, and fatal skin reactions have been reported. These include cases of Stevens-Johnson syndrome, toxic epidermal necrolysis, and erythema multiforme. Hypersensitivity reactions including drug rash with eosinophilia and systemic symptoms (DRESS) have also been reported and were characterized by rash, constitutional findings, and sometimes organ dysfunction.
ADVERSE REACTIONS Clinical Trial Experience: Adults
The incidence of rash was higher in women compared to men in the Intelence arm in the phase 3 trials (rash $ grade 2 was reported in 15% women vs 9.5% men; discontinuations due to rash were reported in 5% women vs 1.9% men). Clinical Trials Experience: Pediatric Subjects (6 years to less than 18 years of age)
Rash was reported more frequently in female subjects than in male subjects (rash $ grade 2 was reported in 20.3% females vs 5.4% males); discontinuations due to rash were reported in 4% of subjects (6.3% females vs 0% males 
